Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "A Press Release on Financial Results which is being submitted to the media is also enclosedherewith".
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Torrent Pharmaceuticals reported standalone net profit of Rs. 2,192 crores for FY26, up 16.1% from Rs. 1,888 crores in FY25. Revenue from operations grew to Rs. 10,498 crores from Rs. 9,485 crores. The Board recommended a final dividend of Rs. 9 per share (180%), following an interim dividend of Rs. 29 per share already paid. Total dividend for FY26 is Rs. 38 per share. The company completed acquisition of controlling stake (46.39%) in J.B. Chemicals & Pharmaceuticals Limited on January 21, 2026, for approximately Rs. 12,537 crores. The Board also sought shareholder approval for QIP issuance up to Rs. 5,000 crores. Debt equity ratio increased to 1.68x from 0.34x due to borrowings for the acquisition.
Strong earnings growth and increased dividend are positive for shareholders, but the large debt-funded acquisition and proposed QIP issuance may cause near-term dilution concerns. The stock may see initial positive reaction to results.